Stockchat.de / Amarillo Biosciences Could Soon Fight Influenza, Cancer,HIV, and More with their Exciting Interferon Patents

Stockchat.de / Amarillo Biosciences Could Soon Fight Influenza, Cancer, HIV, and More with their Exciting Interferon Patents

Amarillo Biosciences (OTCBB: AMARQ), WKN: 917 640, ISIN: US02301P1066 has stumbled into some exciting times, and they currently hold five highly contentious interferon patents in the U.S. These patents have become more valuable to the company in recent months, because of breaking medical research that has shown that interferon treatments can greatly reduce permanent pulmonary damage in victims of different forms of the influenza virus.

With these huge medical breakthroughs and a vicious influenza season in certain regions, Interferon research, technology, and patents could soon be a great investment opportunity for bigger pharmaceutical companies with established distribution chains. Annual interferon sales have exceeded billions of dollars in sales for several years now, and that rate is growing each year.

In addition to fighting long-term influenza symptons, Interferon can be used to treat cancer, multiple sclerosis, fibromyalgia, HIV/AIDS, and HPV. Several recent policy shifts in have opened up potential for further interferon technology use in Europe, which greatly expands the market.

The patents that Amarillo Biosciences holds have been successfully defended in litigation several times, and these patents could be the key to development for further knowledge and use of Interferons. Companies like Hemispherx Biopharma have recently discovered that interferons are a worthwhile investment. Their research told them that low-dose interferon-alpha treatments have been successful in treating the permanent pulmonary damage that the H5N1 and H7N9 influenza strains have been known to cause. These low-dose interferon-alpha treatments are similar to those in which Amarillo Biosciences currently owns five patents.

AMARQ shares fell in price late last year without significant volume from about $0.03 to $0.0008. Recent buying on news of the positive medical studies has led the shares to start rebounding, and they are currently trading at just $0.0054 per share. Further developments on these studies could spark more interest in the interferon industry. AMARQ has a market capitalization of only $395,881, which makes AMARQ an interesting nanocap option.

Für den Inhalt ist ausschließlich der Autor verantwortlich. ***********************************************************

Weitere Information und den Disclaimer finden Sie auf www.Stockchat.de **********************************************************************

(END) Dow Jones Newswires

   February 09, 2014 03:41 ET (08:41 GMT)- - 03 41 AM EST 02-09-14